然而在东亚地区的人群中,有一种常见的基因变异会导致CML患者对伊马替尼产生耐药。 针对这个棘手的难题,杜克-新加坡国立大学医学院(Duke-NUS)的Ong Sin Tiong教授带领团队最近在《白血病》(Leukemia)期刊发表论文,利用开创性的方法揭示了背后机制,由此提出了针对性的破解方案。 根据论文的介绍,东亚地区有12%~15%的人...
参考文献 [1] Hijiya N, Schultz KR, Metzler M, et al. Pediatric chronicmyeloid leukemia is a unique disease that requires a different approach[J]. Blood, 2016, 127(4):392‑399. DOI:10.1182/blood‑2015‑06‑648667. [2] Pulte D, Gondos A, Brenner H. Trends in survival afterdia...
which provided for the development of a clinical staging system: Stage I with none or one factor and a two-year survival rate of 100 percent; Stage II with two or three factors and two-year survival of 72.2 percent; and Stage III with four or five factors and two-year survival of 0 ...
Recent studies in adults allografted in an advanced phase of CML showed no significant differences in OS and leukemia-free survival whether they did or did not have chronic GvHD [55, 56]. These patients are usually not as intensively pre-treated, and thus their graft failure rate might ...
浙江大学博士学位论文CML酪氨酸激酶抑制剂分子靶向药物及异基因造血干细胞移植分层治疗研究姓名:***学位级别:博士专业:内科学(血液病学)指导教师:**20120518浙江大学博士学位论文中文摘要CML酪氨酸激酶抑制剂分子靶向药物及异基因造血干细胞移植分层治疗研究浙江大学医学部博士研究生导师内科学(血液病学)罗依黄河教授中文...
(imatinib, dasatinib, nilotinib, and bosutinib) improved the 10-year survival from 20% to 90%: in acute lymphocytic leukemia improved cure rates from 20% to 60+%; discovery of decitabine for the treatment of myelodys...
Treatment protocols for chronic myelogenous leukemia (CML) are provided below for chronic phase, accelerated phase, and blast phase. General treatment recommendations for chronic myelogenous leukemia Tyrosine kinase inhibitors (TKIs) are the drugs of choice for initial therapy of CML. [1] Imatinib was...
AZD1480 was developed by AstraZeneca as a specific ATP- competitive inhibitor of the JAK2 kinase with an inhibition constant of 260 pM. In enzyme assays, the IC50 for JAK2 is under 1 nM. The IC50 for JAK3 is 14 nM, representing at least 14-fold 1983 Leukemia Chronic myeloproliferative ...
Development of a predictive population survival model according to the cytogenetic response rate for patients with chronic myeloid leukemia in the chronic ... This study sets out to investigate whether the proportion of patients with chronic myeloid leukemia (CML) in the chronic phase who achieve a...
ABSTRACT: Imatinib mesylate has had a significant impact on the survival of patients with chronic myeloid leukemia (CML), particularly chronic-phase (CP) disease. However, a proportion of patients lose their response, fail to respond, or are intolerant to imatinib. The second-generation tyrosine ...